Drug Shortage Report for ACT NABILONE
Report ID | 96733 |
Drug Identification Number | 02393603 |
Brand name | ACT NABILONE |
Common or Proper name | NABILONE |
Company Name | TEVA CANADA LIMITED |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | NABILONE |
Strength(s) | 1MG |
Dosage form(s) | CAPSULE |
Route of administration | ORAL |
Packaging size | 100 |
ATC code | A04AD |
ATC description | ANTIEMETICS AND ANTINAUSEANTS |
Reason for shortage | Other (Please describe in comments) |
Anticipated start date | |
Actual start date | 2019-10-16 |
Estimated end date | |
Actual end date | 2019-10-31 |
Shortage status | Resolved |
Updated date | 2020-03-12 |
Company comments | Item is discontinued, transitioned to the TEVA DIN |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v7 | 2020-03-12 | French | Compare |
v6 | 2020-03-12 | English | Compare |
v5 | 2019-12-19 | French | Compare |
v4 | 2019-12-19 | French | Compare |
v3 | 2019-12-19 | English | Compare |
v2 | 2019-10-17 | French | Compare |
v1 | 2019-10-17 | English | Compare |
Showing 1 to 7 of 7